JP2022520572A5 - - Google Patents

Info

Publication number
JP2022520572A5
JP2022520572A5 JP2021547075A JP2021547075A JP2022520572A5 JP 2022520572 A5 JP2022520572 A5 JP 2022520572A5 JP 2021547075 A JP2021547075 A JP 2021547075A JP 2021547075 A JP2021547075 A JP 2021547075A JP 2022520572 A5 JP2022520572 A5 JP 2022520572A5
Authority
JP
Japan
Application number
JP2021547075A
Other languages
Japanese (ja)
Other versions
JP2022520572A (ja
JPWO2020167376A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/066648 external-priority patent/WO2020167376A1/en
Publication of JP2022520572A publication Critical patent/JP2022520572A/ja
Publication of JP2022520572A5 publication Critical patent/JP2022520572A5/ja
Publication of JPWO2020167376A5 publication Critical patent/JPWO2020167376A5/ja
Priority to JP2024197437A priority Critical patent/JP2025015588A/ja
Withdrawn legal-status Critical Current

Links

JP2021547075A 2019-02-12 2019-12-16 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のcd38細胞膜分子に対するモノクローナル抗体の組み合わせによるalアミロイドーシスの処置 Withdrawn JP2022520572A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024197437A JP2025015588A (ja) 2019-02-12 2024-11-12 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のcd38細胞膜分子に対するモノクローナル抗体の組み合わせによるalアミロイドーシスの処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962804721P 2019-02-12 2019-02-12
US62/804,721 2019-02-12
PCT/US2019/066648 WO2020167376A1 (en) 2019-02-12 2019-12-16 Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024197437A Division JP2025015588A (ja) 2019-02-12 2024-11-12 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のcd38細胞膜分子に対するモノクローナル抗体の組み合わせによるalアミロイドーシスの処置

Publications (3)

Publication Number Publication Date
JP2022520572A JP2022520572A (ja) 2022-03-31
JP2022520572A5 true JP2022520572A5 (https=) 2022-12-22
JPWO2020167376A5 JPWO2020167376A5 (https=) 2022-12-22

Family

ID=69182616

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021547075A Withdrawn JP2022520572A (ja) 2019-02-12 2019-12-16 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のcd38細胞膜分子に対するモノクローナル抗体の組み合わせによるalアミロイドーシスの処置
JP2024197437A Pending JP2025015588A (ja) 2019-02-12 2024-11-12 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のcd38細胞膜分子に対するモノクローナル抗体の組み合わせによるalアミロイドーシスの処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024197437A Pending JP2025015588A (ja) 2019-02-12 2024-11-12 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のcd38細胞膜分子に対するモノクローナル抗体の組み合わせによるalアミロイドーシスの処置

Country Status (17)

Country Link
US (2) US20220213223A1 (https=)
EP (1) EP3923954A1 (https=)
JP (2) JP2022520572A (https=)
KR (1) KR20210143752A (https=)
CN (2) CN119950702A (https=)
AU (2) AU2019429147B2 (https=)
BR (1) BR112021015870A2 (https=)
CA (1) CA3129890A1 (https=)
CL (1) CL2021002140A1 (https=)
EA (1) EA202192235A1 (https=)
IL (1) IL285480A (https=)
JO (1) JOP20210220A1 (https=)
MA (1) MA54923A (https=)
MX (1) MX2021009687A (https=)
PH (1) PH12021551960A1 (https=)
SG (1) SG11202108767PA (https=)
WO (1) WO2020167376A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021552135A1 (en) 2019-03-05 2022-08-31 Prothena Biosciences Ltd Methods of treating al amyloidosis
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US8263746B2 (en) 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
EP2567976B1 (en) 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
DK2237803T3 (en) 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
SG10201604104PA (en) 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods
AU2012328524B2 (en) 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
MX389805B (es) * 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
DK3827845T3 (da) 2015-11-03 2022-05-23 Janssen Biotech Inc Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
WO2018005967A1 (en) * 2016-06-30 2018-01-04 Prothena Therapeutics Limited Compositions for treating amyloidosis

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016142A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)